Clinical Report: Once-Daily Eye Drop for IOP Enters FDA Review

Overview

The FDA has accepted Kowa Pharmaceuticals' NDA for K-911, an investigational once-daily eye drop aimed at lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The NDA is supported by pivotal Phase III trials demonstrating noninferiority to latanoprost.

Background

Intraocular pressure (IOP) management is critical in slowing the progression of glaucoma, a leading cause of blindness. K-911, a nitric oxide-donating bimatoprost, aims to enhance IOP reduction through dual outflow pathways.

Data Highlights

No numerical data available in the source material.

Key Findings

• K-911 is designed to lower IOP through two pathways: conventional and uveoscleral outflow.
• The FDA has set a target action date of April 30, 2027, for the NDA review.
• The NDA is supported by two Phase III trials, Mont Blanc and Denali, comparing K-911 to latanoprost.
• K-911 remains investigational and has not yet received FDA approval.

Clinical Implications

K-911 remains investigational and has not yet received FDA approval.

Conclusion

K-911 remains investigational and has not yet received FDA approval.

Related Resources & Content

1. PR Newswire, 2023 -- Once-Daily Eye Drop for IOP Enters FDA Review
2. Ophthalmology Management — The Latest News in Ophthalmology
3. Ophthalmology Management — QUICK HITS
4. glaucoma physician — Visiox Submits NDA for First Once-daily Brimonidine
5. Retinal Physician — SUBSPECIALTY NEWS: Early anti-VEGF for DR shows no benefit, developments in gene therapy, research on IRD, and more.
6. The Latest News in Ophthalmology
7. QUICK HITS
8. Visiox Submits NDA for First Once-daily Brimonidine
9. Primary Open-Angle Glaucoma Preferred Practice Pattern®
10. A Randomized, Controlled Comparison of NCX 470
11. Frontiers | Efficacy and safety of prostaglandin drugs for elevated intraocular pressure: a Bayesian network meta-analysis